Ambiogen is a spin-out from the Center for Translational Microbiome Research at Karolinska Institutet — operated by researchers who had spent years on the client side of sequencing projects.
Ambiogen is a spin-out from the Center for Translational Microbiome Research (CTMR) at Karolinska Institutet, formed by researchers and technologists with hands-on experience from large-scale microbiome and sequencing-driven research projects.
Our background in translational microbiome research means we understand sequencing from the researcher’s perspective: unclear project definitions, underestimated complexity, missing controls, and data that is technically correct but difficult to interpret or reuse. These are challenges we have worked with directly in academic research environments—and they are the problems Amiogen was created to solve.
The work at CTMR spans complex microbial communities, population-scale studies, and clinically anchored research, all of which rely on careful project planning, robust sequencing strategies, reproducibility, and traceable workflows. That experience directly informs how we design and execute sequencing projects at Ambiogen.
As a company, we combine this research foundation with a technology-driven, automated approach to sequencing services. Our workflows are built for throughput, consistency, and fast turnaround, while maintaining strong documentation and transparent communication throughout the project lifecycle.
Ambiogen works closely with its customers to define sequencing strategies that fit the biological question, practical constraints, and downstream use of the data. We aim to be a collaborative partner—bringing structure, clarity, and technical depth to sequencing projects of any complexity.
Research Scientist
CTO
Research Scientist
CEO